A Phase I/II Trial of ACA 125 in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Peritoneal Cancer
Patients with epithelial ovarian, fallopian tube or peritoneal cancer who receive surgical
cytoreduction and platinum/taxane containing chemotherapy have a significant chance of
entering complete clinical remission but about 70% will eventually relapse. Many patients
respond to additional cytotoxic treatment with partial or complete responses, yet
approximately 100% of these patients will ultimately progress. Novel consolidation
strategies following treatment for recurrent disease are needed and an immunologic approach
is an attractive option.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention
Safety, feasibility and tolerability
Jacobus Pfisterer, Prof. Dr.
AGO Study Group